WJ460
Based on 3 publication(s) in Google Scholar
WJ460 is a potent inhibitor of myoferlin (MYOF) that interacts directly with MYOF. WJ460 inhibits the migration and growth, induces cell cycle arrest, mitochondrial autophagy, lipid peroxidation and ferroptosis in tumor cells. WJ460 has anti-tumor activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 1415251-36-3
- Formule: C27H28N2O3S
- Masse moléculaire:460.59
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Ferroptosis Compound Library
HY-L051
-
Anti-Breast Cancer Compound Library
HY-L074
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) WJ460
More
Activité biologique
MYOF[1]
WJ460 (50 nM; 16-24 h) induces G2/M phase arrest, mitochondrial autophagy, lipid peroxidation and ferroptosis in PDAC cell lines[1].
WJ460 (1-100 nM; 12 h) blocks the invasion of breast cancer cells, significantly inhibits the invasion of MDA-MB-231 and BT549 cells through collagen I, and the IC50 values in MDA-MB-231 of 43.37 nM and 36.40 nM in BT549 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PDAC cell lines
-
Concentration:50 nM
-
Incubation Time:16 and 24 h
-
Result:Decreased mitochondrial ROS abundance.
-
Cell Line:PaTu 8988T and HPNE cells
-
Concentration:50 nM
-
Incubation Time:8, 10, 12 and 24 h
-
Result:Reduced the levels of SLC7A11 and GPX-4.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MDA-MB-231-Luciferase cells treated athymic nude mice[2]
-
Dosage:5 and 10mg/kg
-
Administration:Intraperitoneal injection (i.p.); single dose
-
Result:Significantly inhibited breast cancer pulmonary metastasis in a concentration-dependent manner.
Inhibited the proliferation of MDA-MB-231 cells.
Increased mouse overall survival.
Chemical Information
-
CAS No. 1415251-36-3
-
Appearance Solid
-
Masse moléculaire 460.59
-
Formule C27H28N2O3S
-
Color Light yellow to yellow
-
SMILES
O=C(NCCCCC1=CC=CC=C1)C2=CC=CC(C(N3C4=CC=CC=C4OC)SCC3=O)=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
EMBO J
Targeting myoferlin in ER/Golgi vesicle trafficking reprograms pancreatic cancer-associated fibroblasts. [Abstract]2025 Oct 8. PMID: 41062852 -
Gastric Cancer
Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance. [Abstract]2021 Nov;24(6):1264-1277. PMID: 34272617 -
PLoS Pathog
2023 Feb 24;19(2):e1011202. PMID: 36827461
Solvant et solubilité
DMSO : 250 mg/mL (542.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.52 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Rademaker G, et al. Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Redox Biol. 2022 Jul;53:102324. [Content Brief]
[2]. Zhang T, et al. A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer. Nat Commun. 2018 Sep 13;9(1):3726. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1711 mL | 10.8556 mL | 21.7113 mL | 54.2782 mL |
| 5 mM | 0.4342 mL | 2.1711 mL | 4.3423 mL | 10.8556 mL | |
| 10 mM | 0.2171 mL | 1.0856 mL | 2.1711 mL | 5.4278 mL | |
| 15 mM | 0.1447 mL | 0.7237 mL | 1.4474 mL | 3.6185 mL | |
| 20 mM | 0.1086 mL | 0.5428 mL | 1.0856 mL | 2.7139 mL | |
| 25 mM | 0.0868 mL | 0.4342 mL | 0.8685 mL | 2.1711 mL | |
| 30 mM | 0.0724 mL | 0.3619 mL | 0.7237 mL | 1.8093 mL | |
| 40 mM | 0.0543 mL | 0.2714 mL | 0.5428 mL | 1.3570 mL | |
| 50 mM | 0.0434 mL | 0.2171 mL | 0.4342 mL | 1.0856 mL | |
| 60 mM | 0.0362 mL | 0.1809 mL | 0.3619 mL | 0.9046 mL | |
| 80 mM | 0.0271 mL | 0.1357 mL | 0.2714 mL | 0.6785 mL | |
| 100 mM | 0.0217 mL | 0.1086 mL | 0.2171 mL | 0.5428 mL |
WJ460 Related Classifications
HY-124632 Related Classifications
Powered by Bioz